Skip to main content

Specialized Programs of Research Excellence (SPOREs)

In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). Each SPORE focuses on a specific organ site, such as breast or lung cancer, or on a group of highly related cancers, such as gastrointestinal cancers. SPOREs are designed to enable the rapid and efficient movement of basic scientific findings into clinical settings, as well as to determine the biological basis for observations made in individuals with cancer or in populations at risk for cancer. Total funding shown represents the SPORE program using relevant P50s, P20s, U54s, and co-funded grants external to NCI.

The Translational Research Program (TRP) is the home of the SPOREs, a cornerstone of NCI’s efforts to promote collaborative, interdisciplinary translational cancer research. SPORE grants involve both basic and clinical/applied scientists, and support projects that will result in new and diverse approaches to the prevention, early detection, diagnosis, and treatment of human cancers. For more information on these SPORE grants and organ sites, please visit the Translational Research Program.

NCI's Center to Reduce Cancer Health Disparities (CRCHD) is home to the P20 SPORE grants. These P20 grants support feasibility and planning activities to build research programs addressing cancer health disparities as a cross-cutting research theme. For more information on these SPORE grants, please visit the CRCHD's Funding Opportunities for Research and Training page.

The NCI Funded Research Portfolio (NFRP) web site contains additional information about the SPORE grants listed below that have been funded by NCI. The NFRP provides access to various NCI budget reports that contain information about research funding according to specific research categories. For more detailed information on all SPORE grants, please visit the NCI Funded Research Portfolio.

FY 2018 Funding for SPORE Grants
(Whole Dollars)
Mechanism Site Amount
P50 SPOREs Bladder $3,462,446
Brain 9,398,496
Breast 8,385,586
Cervical 2,251,770
Endometrial 2,460,692
Gastrointestinal (GI) 5,000,000
Head and Neck 1,950,000
Hepatobiliary 2,300,000
Kidney 4,600,000
Leukemia 6,059,026
Lung 7,168,934
Lymphoma 9,549,373
Myeloma 2,538,499
Neuroendocrine 2,300,000
Ovarian 8,356,367
Pancreatic 6,897,971
Prostate 16,911,796
Sarcoma 2,286,505
Skin 5,300,000
Thyroid 2,136,667
  Subtotal $109,314,128
P20 SPOREs Breast 2,051,751
Gastrointestinal (GI) 1,062,400
Prostate 1,083,300
Subtotal $4,197,451
U54 SPOREs Hyperactive RAS $2,102,055
Subtotal $2,102,055
Co-funded Head & Neck $216,200
  Total Co-funded $216,200
Total Number of SPOREs, Total SPORE Funding $115,829,834
  • Posted: